Chris Ehrlich is the founder of Cero Therapeutics. Latest round: Series D. Based in South San Francisco, California.
Chris Ehrlich is the Chief Executive Officer of CERo Therapeutics, a clinical-stage immunotherapy company developing next-generation engineered T cell therapies (CER-T) to treat solid and hematological tumors. He leads the company's efforts in combining innate and adaptive immunity to enhance the body's ability to eliminate tumors.
Full founder directory · Investor directory · Company funding database · Fundraising library